PND12 COST-EFFECTIVENESS OF RASAGILINE VERSUS ROPINIROLE EXTENDED RELEASE IN DELAYING LEVODOPA IN THE TREATMENT OF EARLY PARKINSONS DISEASE IN THE UNITED STATES
May 1, 2009, 00:00
10.1016/S1098-3015(10)74019-5
https://www.valueinhealthjournal.com/article/S1098-3015(10)74019-5/fulltext
Title :
PND12 COST-EFFECTIVENESS OF RASAGILINE VERSUS ROPINIROLE EXTENDED RELEASE IN DELAYING LEVODOPA IN THE TREATMENT OF EARLY PARKINSONS DISEASE IN THE UNITED STATES
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)74019-5&doi=10.1016/S1098-3015(10)74019-5
First page :
Section Title :
Open access? :
No
Section Order :
513